5/29/2023 0 Comments Dc impairments ioffRequiring immunosuppressive therapy or for a platelet count higher than 30,000 but not higher than 50,000, with history of hospitalization because of severe bleeding requiring intravenous immune globulin, high-dose parenteral corticosteroids, and platelet transfusions Requiring chemotherapy for chronic refractory thrombocytopenia or a platelet count 30,000 or below despite treatment Any reduction in evaluation based upon that or any subsequent examination shall be subject to the provisions of § 3.105(e) of this chapter Six months following hospital discharge or, in the case of chemotherapy treatment, six months after completion of treatment, the appropriate disability rating shall be determined by mandatory VA examination. Note (3): A 100 percent evaluation shall be assigned as of the date of hospital admission for peripheral blood or bone marrow stem cell transplant or during the period of treatment with chemotherapy (including myelosuppressants). Note (2): If the condition undergoes leukemic transformation, evaluate as leukemia under diagnostic code 7703 Note (1): Rate complications such as hypertension, gout, stroke, or thrombotic disease separately Requiring phlebotomy 3 or fewer times per 12-month period or if requiring biologic therapy or interferon on an intermittent basis as needed to maintain all blood values at reference range levels Requiring phlebotomy 4-5 times per 12-month period, or if requiring continuous biologic therapy or myelosuppressive agents, to include interferon, to maintain platelets <200,000 or white blood cells (WBC) <12,000 Requiring phlebotomy 6 or more times per 12-month period or molecularly targeted therapy for the purpose of controlling RBC count Requiring peripheral blood or bone marrow stem-cell transplant or chemotherapy (including myelosuppressants) for the purpose of ameliorating the symptom burden ![]() Myeloproliferative Disorders: (Diagnostic Codes 7704, 7718, 7719) Note (3): Evaluate residuals of leukemia or leukemia therapy under the appropriate diagnostic code(s). Note (2): Evaluate symptomatic chronic lymphocytic leukemia that is at Rai Stage I, II, III, or IV the same as any other leukemia evaluated under this diagnostic code If there has been no recurrence, rate on residuals Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of § 3.105(e) of this chapter. Six months after discontinuance of such treatment, the appropriate disability rating shall be determined by mandatory VA examination. Note (1): A 100 percent evaluation shall continue beyond the cessation of any surgical therapy, radiation therapy, antineoplastic chemotherapy, or other therapeutic procedures. Otherwise rate residuals under the appropriate diagnostic code(s)Ĭhronic lymphocytic leukemia or monoclonal B-cell lymphocytosis (MBL), asymptomatic, Rai Stage 0 When there is active disease or during a treatment phase ![]() Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of § 3.105(e) of this chapterħ703 Leukemia (except for chronic myelogenous leukemia): Note: A 100 percent evaluation for bone marrow transplant shall be assigned as of the date of hospital admission and shall continue with a mandatory VA examination six months following hospital discharge. Requiring continuous medication (e.g., antibiotics) for control or requiring intermittent use of a myeloid growth factor to maintain ANC greater than or equal to 1500/µl Requiring intermittent myeloid growth factors to maintain ANC greater than 1000/µl or infections recurring, on average, at least once per 12-month period but less than once every three months per 12-month period Requiring intermittent myeloid growth factors (granulocyte colony-stimulating factor (G-CSF) or granulocyte-macrophage colony-stimulating factor (GM-CSF) or continuous immunosuppressive therapy such as cyclosporine to maintain absolute neutrophil count (ANC) greater than 500/microliter (µl) but less than 1000/µl or infections recurring, on average, at least once every three months per 12-month period Requiring bone marrow transplant or infections recurring, on average, at least once every six weeks per 12-month period
0 Comments
Leave a Reply. |